CN100570365C - 抗体或嗜中性粒细胞介导的臭氧产生 - Google Patents

抗体或嗜中性粒细胞介导的臭氧产生 Download PDF

Info

Publication number
CN100570365C
CN100570365C CNB2003801087252A CN200380108725A CN100570365C CN 100570365 C CN100570365 C CN 100570365C CN B2003801087252 A CNB2003801087252 A CN B2003801087252A CN 200380108725 A CN200380108725 A CN 200380108725A CN 100570365 C CN100570365 C CN 100570365C
Authority
CN
China
Prior art keywords
antibody
active oxygen
neutrophil cell
oxygen
ozone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801087252A
Other languages
English (en)
Chinese (zh)
Other versions
CN1739028A (zh
Inventor
P·温特沃斯
R·A·勒纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Novartis AG
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Scripps Research Institute filed Critical Novartis AG
Publication of CN1739028A publication Critical patent/CN1739028A/zh
Application granted granted Critical
Publication of CN100570365C publication Critical patent/CN100570365C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNB2003801087252A 2002-11-14 2003-11-13 抗体或嗜中性粒细胞介导的臭氧产生 Expired - Fee Related CN100570365C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42624502P 2002-11-14 2002-11-14
US60/426,245 2002-11-14

Publications (2)

Publication Number Publication Date
CN1739028A CN1739028A (zh) 2006-02-22
CN100570365C true CN100570365C (zh) 2009-12-16

Family

ID=32313124

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801087252A Expired - Fee Related CN100570365C (zh) 2002-11-14 2003-11-13 抗体或嗜中性粒细胞介导的臭氧产生

Country Status (8)

Country Link
US (1) US20060292076A1 (enExample)
EP (1) EP1563299A2 (enExample)
JP (1) JP2006506613A (enExample)
CN (1) CN100570365C (enExample)
AU (1) AU2003288058A1 (enExample)
BR (1) BR0315628A (enExample)
CA (1) CA2505923A1 (enExample)
WO (1) WO2004044582A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4998230B2 (ja) * 2007-11-26 2012-08-15 株式会社島津製作所 タンパク質試料中のメチオニン残基の酸化状態を解析する方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846959A (en) * 1992-10-30 1998-12-08 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US20020031522A1 (en) * 1996-03-11 2002-03-14 David Baltimore Truncated crafi inhibits cd40 signaling

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684521A (en) * 1982-12-08 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5162217A (en) * 1984-08-27 1992-11-10 Bio-Technology General Corp. Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda PL promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof
US6030611A (en) * 1984-08-27 2000-02-29 Bio-Technology General Corp. Therapeutic SOD compositions and uses thereof
US5248603A (en) * 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
DE3619436A1 (de) * 1986-06-10 1987-12-17 Bayer Ag Triaryl- und trihetarylmethanderivate als redoxindikatoren und deren verwendung
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
DE4038563A1 (de) * 1990-12-04 1992-06-11 Gruenenthal Gmbh Verwendung von superoxiddismutasen zur prophylaxe und/oder behandlung von organversagen bei risikopatienten mit polytrauma
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
US5599712A (en) * 1993-10-15 1997-02-04 University Of Pittsburgh Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
US5647315A (en) * 1994-10-07 1997-07-15 Yamaha Hatsudoki Kabushiki Kaisha Lubricating arrangement for engine
JPH08249306A (ja) * 1995-03-09 1996-09-27 Sharp Corp データ駆動型情報処理装置
AU2394597A (en) * 1996-04-18 1997-11-07 Medical Research Council Oxidative metabolism in smooth muscle cells: methods and materials relating thereto
GB9621440D0 (en) * 1996-10-15 1996-12-04 Renold Plc A chain tensioner
GB9622159D0 (en) * 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
US6040611A (en) * 1998-09-10 2000-03-21 Hughes Electonics Corporation Microelectromechanical device
EP1153010A1 (en) * 1999-02-08 2001-11-14 Checkpoint Genetics, Inc. $i(N)-SUBSTITUTED AMINO ACIDS, ANTIOXIDANT PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS USING SAME

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846959A (en) * 1992-10-30 1998-12-08 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US20020031522A1 (en) * 1996-03-11 2002-03-14 David Baltimore Truncated crafi inhibits cd40 signaling

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Decreased plasma superoxide scavenging activity inimmunological disorders-carboxyethylgermanium sesquioxide(Ge-132) as a promoter of prednisolone.L.Pronai,S.Arimori.Biotherapy,Vol.4. 1992 *
Luminol-dependent chemiluminescence produced byneutrophils stimulated by immune complexes. Kee Cheung,Anna C.Archibald,Michael F.Robinson.Aust.J.Exp.Biol.Med.Sci.,Vol.62 No.4. 1984 *

Also Published As

Publication number Publication date
EP1563299A2 (en) 2005-08-17
WO2004044582A2 (en) 2004-05-27
BR0315628A (pt) 2005-08-23
AU2003288058A1 (en) 2004-06-03
JP2006506613A (ja) 2006-02-23
WO2004044582A3 (en) 2004-09-16
US20060292076A1 (en) 2006-12-28
CN1739028A (zh) 2006-02-22
AU2003288058A8 (en) 2004-06-03
CA2505923A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
Plumet et al. Bacteriophage therapy for Staphylococcus aureus infections: a review of animal models, treatments, and clinical trials
Coelho et al. Biochemical screening for SARS-CoV-2 main protease inhibitors
Xia et al. Retuning Mitochondrial Apoptosis/Mitophagy Balance via SIRT3‐Energized and Microenvironment‐Modulated Hydrogel Microspheres to Impede Osteoarthritis
Bansal et al. Naringenin protects against oxido-inflammatory aberrations and altered tryptophan metabolism in olfactory bulbectomized-mice model of depression
Saha et al. Idiopathic pulmonary fibrosis (IPF): disease pathophysiology, targets, and potential therapeutic interventions
Guo et al. Irisin Rescues Blood‐Brain Barrier Permeability Following Traumatic Brain Injury and Contributes to the Neuroprotection of Exercise in Traumatic Brain Injury
Muhlestein et al. Chronic infection and coronary artery disease
Fan et al. Activation of interleukin-1β release by the classical swine fever virus is dependent on the NLRP3 inflammasome, which affects virus growth in monocytes
He et al. The functional role of fecal microbiota transplantation on dextran sulfate sodium-induced colitis in mice
Hulscher et al. Clinical approach to post-acute sequelae after COVID-19 infection and vaccination
Wang et al. Cannabidiol protects the liver from α-Amanitin-induced apoptosis and oxidative stress through the regulation of Nrf2
Ren et al. Inhibition of porcine epidemic diarrhea virus by cinchonine via inducing cellular autophagy
Wasso et al. Toxicity and anthelmintic efficacy of chitosan encapsulated bromelain against gastrointestinal strongyles in Small East African goats in Kenya
Hudson et al. Comparison of the antiviral effects of naturally occurring thiophenes and polyacetylenes
CA2422586A1 (en) Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
AU2002212970A1 (en) Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
Piotrowsky et al. Analysis of high-dose ascorbate-induced cytotoxicity in human glioblastoma cells and the role of dehydroascorbic acid and iron
Jiang et al. Pectolinarigenin targeting FGFR3 alleviates osteoarthritis progression by regulating the NF-κB/NLRP3 inflammasome pyroptotic pathway
US20070009537A1 (en) Antimicrobial activity of antibodies producing reactive oxygen species
US20050129680A1 (en) Antimicrobial activity of antibodies
US20040157280A1 (en) Antibody mediated ozone generation
US20060292076A1 (en) Antimicrobial mediated ozone generation
Tavares et al. Umbelliferone reduces inflammation and ligature‐induced osteoclastic alveolar bone resorption in mice
Abudouaini et al. Activating the iNOS regulatory pathway by arginine deprivation targets energy metabolism to induce autophagy-dependent apoptosis against spinal echinococcosis
Peng et al. TAS4464, a neddylation inhibitor, mitigates Staphylococcus aureus-induced periprosthetic joint infection by modulating immunosuppressive cell functions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: E. W. SCRIPPS INSTTUTE

Free format text: FORMER OWNER: NOVANNIS COMPANY; APPLICANT

Effective date: 20080516

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080516

Address after: American California

Applicant after: The Scripps Research Inst.

Address before: Basel, SUI

Applicant before: Novartis

Co-applicant before: The Scripps Research Inst.

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091216

Termination date: 20101113